Even with breakthroughs, treatment for advanced squamous cell carcinoma is more complex. Patients often need more than one treatment. Many patients with this advanced cancer are cared for by a team of ...

New study corroborates DecisionDx ®-SCC's ability to independently predict metastatic risk in patients with high-risk cutaneous squamous cell carcinoma (SCC) Landmark analysis of nearly 10,000 ...

Reolysin and Tecentriq combination therapy achieved a 29% objective response rate in third-line metastatic squamous cell anal ...

DecisionDx-SCC test predicts local recurrence and metastasis in high-risk cutaneous squamous cell carcinoma, enhancing personalized treatment decisions. The test categorizes patients into three risk ...

New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma (SCC) demonstrates that the addition of DecisionDx-SCC to Brigham & Women's Hospital (BWH) staging ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share data supporting its dermatologic ...

Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Sun Pharmaceuticals for UNLOXCYT ™ (cosibelimab-ipdl). UNLOXCYT is the first and ...

Castle Biosciences (CSTL) announced the publication of two new studies related to its DecisionDx-SCC test, adding to its validated uses for patients with high-risk cutaneous squamous cell carcinoma.

Maxillary squamous cell carcinoma (MSCC) represents a relatively uncommon subset of head and neck cancers; however, its aggressive nature and propensity for early cervical lymph node involvement ...

Nearly one-third of patients who responded to a survey did not understand common skin cancer terms frequently used by ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data on its ...